Parkinson's disease, primates, and gene therapy: Vive la différence?

Target validation: the Parkinson disease perspective

(2010) D. G. Standaert et al.   Disease Models & Mechanisms

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

(2010) William J Marks et al.   LANCET NEUROLOGY

Safety Evaluation of AAV2-GDNF Gene Transfer into the Dopaminergic Nigrostriatal Pathway in Aged and Parkinsonian Rhesus Monkeys

(2009) Xiaomin Su et al.   HUMAN GENE THERAPY

Axonal Transport Defects in Neurodegenerative Diseases

(2009) G. A. Morfini et al.   JOURNAL OF NEUROSCIENCE

Nigrostriatal rAAV-mediated GDNF Overexpression Induces Robust Weight Loss in a Rat Model of Age-related Obesity

(2009) Fredric P Manfredsson et al.   MOLECULAR THERAPY

EXPRESSION, BIOACTIVITY, AND SAFETY 1 YEAR AFTER ADENO-ASSOCIATED VIRAL VECTOR TYPE 2–MEDIATED DELIVERY OF NEURTURIN TO THE MONKEY NIGROSTRIATAL SYSTEM SUPPORT CERE-120 FOR PARKINSON'S DISEASE

(2009) Christopher D. Herzog et al.   NEUROSURGERY

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

(2008) William J Marks et al.   LANCET NEUROLOGY

Design of clinical trials of gene therapy in Parkinson disease

(2007) Travis B. Lewis et al.   EXPERIMENTAL NEUROLOGY